



Klinik für Urologie: Erfasste Publikationen aus 2021

ID: 416109

Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer.

Abdom Radiol (NY) 2021; 46(6): 2751-2759; Impact Factor=2.886; Impact Factor 2024=2.2;

Typ=Journal Article;

Valentin B, Schimmöller L, Ullrich T, Klingebiel M, Demetrescu D, Sawicki LM, Lakes J, Mally D,

Quentin M, Esposito I, Albers P, Antoch G, Arsov C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 426074

Robot-assisted Lymphadenectomy for Patients with non-seminomatous Germ Cell Tumors Comment

Aktuelle Urol 2021; 52(01): 18-19; Impact Factor=0.465; Impact Factor 2024=0.4; Typ=Editorial

Material;

Hiester A, Albers P

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 474525

The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.

Anticancer Res 2021; 41(12): 5987-5996; Impact Factor=2.435; Impact Factor 2024=1.7; Typ=Journal Article;

Okubo K, REßING N, Schulz WA, Hansen FK, Asano T, Sato A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465842

Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.

Anticancer Res 2021; 41(6): 2901-2912; Impact Factor=2.435; Impact Factor 2024=1.7; Typ=Journal Article;

Okubo K, Isono M, Asano T, REßING N, Schulz WA, Hansen FK, Sato A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465384

Molecular and epigenetic pathogenesis of germ cell tumors.

Asian J Urol 2021; 8(2): 144-154; Impact Factor=n.a.; Impact Factor 2024=2.4; Typ=Journal Article;Review;

Müller MR, Skowron MA, Albers P, Nettersheim D

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465385

Surgical treatment of metastatic germ cell cancer.

Asian J Urol 2021; 8(2): 155-160; Impact Factor=n.a.; Impact Factor 2024=2.4; Typ=Journal Article;Review;

Hiester A, Albers P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465386

Treatment of clinical stage I non-seminoma.

Asian J Urol 2021; 8(2): 161-169; Impact Factor=n.a.; Impact Factor 2024=2.4; Typ=Journal

Article;Review;

Winter C, Hiester A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465333

Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.

BJU Int 2021; 128(5): 607-614; Impact Factor=5.969; Impact Factor 2024=4.5; Typ=Journal

Article;Multicenter Study;

Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, **Grunewald CM, Niegisch G**, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 472036

KDM6A mutations promote acute cytoplasmic DNA release, DNA damage response and mitosis defects.

BMC Mol Cell Biol 2021; 22(1): ; Impact Factor=2.813; Impact Factor 2024=2.7; Typ=Journal Article;

Koch J, Lang A, **Whongsiri P, Schulz WA, Hoffmann MJ**, Greife A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 415022

Clinical dilemmas in local and regional testis cancer.

Can Urol Assoc J 2021; 15(1): E58-E64; Impact Factor=2.052; Impact Factor 2024=2.0; Typ=Journal

Article;Review;

Nason GJ, Rendon RA, Wood L, Huddart RA, **Albers P**, Einhorn LH, Nichols CR, Kollmannsberger C, Anson-Cartwright L, Warde P, Jewett MAS, Chung P, Bedard PL, Hansen AR, Hamilton RJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469159

The developmental origin of cancers defines basic principles of cisplatin resistance.

Cancer Lett 2021; 519(): 199-210; Impact Factor=9.756; Impact Factor 2024=10.1; Typ=Journal Article;

Skowron MA, Oing C, Bremmer F, Ströbel P, Murray MJ, Coleman N, Amatruda JF, Honecker F, Bokemeyer C, **Albers P, Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 475820

Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma

Cancers (Basel) 2021; 13(23): ; Impact Factor=6.575; Impact Factor 2024=4.4; Typ=

Hoffmann MJ, Schulz WA

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 429983

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.

Cancers (Basel) 2021; 13(6): ; Impact Factor=6.575; Impact Factor 2024=4.4; Typ=Journal Article;

Thy S, Hommel A, Meneceur S, Bartkowiak AL, Schulz WA, Niegisch G, Hoffmann MJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 417244

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.

Diagnostics (Basel) 2021; 11(1): ; Impact Factor=3.992; Impact Factor 2024=3.3; Typ=Journal Article;

Szarvas T, **Hoffmann MJ**, Olah C, Szekely E, Kiss A, Hess J, Tschirdewahn S, Hadaschik B, Grotheer V, Nyirady P, Csizmarik A, Varadi M, Reis H

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469469

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.

Eur J Cancer 2021; 155(): 64-72; Impact Factor=10.002; Impact Factor 2024=7.1; Typ=Journal Article; **Hiester A**, **Fingerhut A**, **Niegisch G**, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Loy V, Wittekind C, Hartmann M, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 470154

Comparison and prediction of artefact severity due to total hip replacement in 1.5 T versus 3 T MRI of the prostate.

Eur J Radiol 2021; 144(): ; Impact Factor=4.531; Impact Factor 2024=3.3; Typ=Journal Article; Boschheidgen M, Ullrich T, Blondin D, Ziayee F, Kasproski L, Ljimini A, **Arsov C**, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 427908

PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.

Eur J Radiol 2021; 136(): ; Impact Factor=4.531; Impact Factor 2024=3.3; Typ=Journal Article; Morawitz J, Kirchner J, **Lakes J**, Bruckmann NM, Mamlins E, **Hiester A**, Aissa J, Loberg C, Schimmöller L, **Arsov C**, Antke C, **Albers P**, Antoch G, Sawicki LM

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 429949

Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy.

Eur J Radiol 2021; 137(): ; Impact Factor=4.531; Impact Factor 2024=3.3; Typ=Journal Article; Klingebiel M, **Arsov C**, Ullrich T, Quentin M, **Al-Monajjed R**, **Mally D**, Sawicki LM, **Hiester A**, Esposito I, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469929

Addressing Equality of Representation in Urology Societies.

Eur Urol 2021; 80(4): 454-455; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Editorial; Chapple CR, **Albers P**, Denstedt J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469681

Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.

Eur Urol 2021; 79(3): 327-329; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Editorial; Van Poppel H, Hogenhout R, **Albers P**, van den Bergh RCN, Barentsz JO, Roobol MJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383585

Re: The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.

Eur Urol 2021; 79(1): 160-161; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Journal Article;
Albers P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 467117

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021.

Eur Urol 2021; 80(1): 4-6; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Editorial;
Fankhauser CD, Oldenburg J, **Albers P**, Algaba F, Bokemeyer C, Boormans JL, Fischer S, Fizazi K, Gremmels H, Mayor de Castro J, Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 467328

Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. **Eur Urol** 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy.

Eur Urol 2021; 80(1): e28-e29; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Letter;
Van Poppel H, Hogenhout R, **Albers P**, van den Bergh RCN, Barentsz JO, Roobol MJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465695

Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).

Eur Urol 2021; 79(6): 750-759; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Journal Article;
Stolzenburg JU, Holze S, Neuhaus P, Kyriazis I, Do HM, Dietel A, Truss MC, Grzella CI, Teber D, Hohenfellner M, **Rabenalt R**, **Albers P**, Mende M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 467592

Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?

Eur Urol 2021; 80(2): 127-128; Impact Factor=24.267; Impact Factor 2024=25.2; Typ=Editorial;
Woodruff P, Wallis CJD, **Albers P**, Klaassen Z

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 473560

A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.

Eur Urol Oncol 2021; 4(5): 731-739; Impact Factor=8.208; Impact Factor 2024=9.3; Typ=Journal Article;Review;

Van Poppel H, Hogenhout R, **Albers P**, van den Bergh RCN, Barentsz JO, Roobol MJ

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 484903

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.

Front Immunol 2021; 12(:) ; Impact Factor=8.786; Impact Factor 2024=5.9; Typ=Journal

Article;Research Support, Non-U.S. Gov't;

Grunewald CM, Haist C, **König C**, Petzsch P, Bister A, Nößner E, Wiek C, Scheckenbach K, Köhrer K, **Niegisch G**, Hanenberg H, **Hoffmann MJ**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 426082

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.

Genes (Basel) 2021; 12(2): ; Impact Factor=4.141; Impact Factor 2024=2.8; Typ=Journal Article;

Hoffmann MJ, **Meneceur S**, **Hommel K**, **Schulz WA**, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348876

The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction.

Histopathology 2021; 78(4): 593-606; Impact Factor=7.778; Impact Factor 2024=4.1; Typ=Journal Article;

Fichtner A, Richter A, Filmar S, Gaisa NT, Schweyer S, Reis H, **Nettersheim D**, Oing C, Gayer FA, Leha A, Küffer S, Ströbel P, Kaulfuß S, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 427917

Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention.

Int J Cancer 2021; 148(12): 3086-3096; Impact Factor=7.316; Impact Factor 2024=4.7; Typ=Consensus Development Conference;Journal Article;Research Support, Non-U.S. Gov't;

Gillmann C, Pajor G, Ramadori P, **Albers P**, Mons U, Steindorf K, Kentner S, Baumann M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 427918

Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

J Cancer Res Clin Oncol 2021; 147(4): 1273-1274; Impact Factor=4.322; Impact Factor 2024=2.8; Typ=Letter;

Wiegel T, **Albers P**, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 314885

Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).

J Cancer Res Clin Oncol 2021; 147(1): 235-242; Impact Factor=4.322; Impact Factor 2024=2.8; Typ=Journal Article;

Wiegel T, **Albers P**, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 415000

The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours.

J Cell Mol Med 2021; 25(3): 1394-1405; Impact Factor=5.295; Impact Factor 2024=4.2; Typ=Journal

Article;Research Support, Non-U.S. Gov't;

Wruck W, Bremmer F, **Kotthoff M**, Fichtner A, **Skowron MA**, Schönberger S, Calaminus G, Vokuhl C, Pfister D, Heidenreich A, **Albers P**, Adjaye J, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465718

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.

J Clin Oncol 2021; 39(14): 1563-1574; Impact Factor=50.717; Impact Factor 2024=43.4; Typ=Journal Article;

Gillessen S, Sauv  N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, **Lorch A**, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn DJ, Sternberg CN, Heidenreich A, Beyer J, International Germ Cell Cancer Classification Update Consortium

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465717

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.

J Clin Oncol 2021; 39(14): 1553-1562; Impact Factor=50.717; Impact Factor 2024=43.4; Typ=Journal Article;

Beyer J, Collette L, Sauv  N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, **Lorch A**, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S, International Germ Cell Cancer Classification Update Consortium

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469188

The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors.

J Exp Clin Cancer Res 2021; 40(1): ; Impact Factor=12.658; Impact Factor 2024=12.8; Typ=Journal Article;

Miranda-Gon alves V, Lobo J, Guimar es-Teixeira C, Barros-Silva D, Guimar es R, Cantante M, Braga I, Maur cio J, Oing C, Honecker F, **Nettersheim D**, Looijenga LHJ, Henrique R, Jer nimo C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469183

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.

J Immunother Cancer 2021; 9(8): ; Impact Factor=12.469; Impact Factor 2024=10.6; Typ=Journal Article;

Kl mper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, **Rehlinghaus M**, **Hoffmann MJ**, **Niegisch G**, Uhlig A, Trojan L, Steinestel J, Steinestel K, Wirtz RM, Sikic D, Eckstein M, Kristiansen G, Toma M, H lzel M, Ritter M, Strieth S, Ellinger J, Dietrich D

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465184

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol 2021; 22(4): 525-537; Impact Factor=54.433; Impact Factor 2024=35.9; Typ=Journal Article;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;

Bellmunt J, Hussain M, Gschwend JE, **Albers P**, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T, IMvigor010 Study Group
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465832

Arterial spin labelling as a gadolinium-free alternative in the detection of prostate cancer.

Magn Reson Imaging 2021; 80(): 33-38; Impact Factor=3.13; Impact Factor 2024=2.0; Typ=Journal Article;

Boschheidgen M, Schimmöller L, Kasprowski L, Abrar D, **Arsov C**, **Albers P**, Antoch G, Wittsack HJ, Ullrich T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 488599

Cultivation of Testicular Germ Cell Cancer Cell Lines and Establishment of Gene-Edited Subclones Using CRISPR/Cas9.

Methods Mol Biol 2021; 2195(): 85-97; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;

Jostes S, **Nettersheim D**, Schneider S, Schorle H

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 590437

Evaluation of Chemotherapeutic Drugs for Treatment of (Cisplatin-Resistant) Germ Cell Cancer Cell Lines.

Methods Mol Biol 2021; 2195(): 99-111; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;

Skowron MA, **Hoffmann MJ**, **Watolla MM**, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 590436

Three-Dimensional Cultivation of Germ Cell Cancer Cell Lines as Hanging Drops.

Methods Mol Biol 2021; 2195(): 77-83; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;

Skowron MA, **Watolla MM**, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 429414

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.

Molecules 2021; 26(5): ; Impact Factor=4.927; Impact Factor 2024=4.6; Typ=Journal Article;

Berning L, Schlütermann D, Friedrich A, Berleth N, Sun Y, Wu W, Mendiburo MJ, Deitersen J, Brass HUC, **Skowron MA**, **Hoffmann MJ**, **Niegisch G**, Pietruszka J, Stork B

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465952

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.

Nature 2021; 595(7867): 432-437; Impact Factor=69.504; Impact Factor 2024=48.5; Typ=Journal Article;

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, **Albers P**, Castellano D, Nishiyama H, Daneshmand S, Sharma S,

Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 466850

On the origin of germ cell neoplasia in situ: Dedifferentiation of human adult Sertoli cells in cross talk with seminoma cells in vitro *

Neoplasia 2021; 23(7): 731-742; Impact Factor=6.218; Impact Factor 2024=7.7; Typ=

Fink C, Baal N, Wilhelm J, Sarode P, Weigel R, Schumacher V, **Nettersheim D**, Schorle H, Schroeck C, Bergmann M, Kliesch S, Kressin M, Savai R

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 418300

[PSMA radioligand therapy could pose infrastructural challenges for nuclear medicine: results of a basic calculation for the capacity planning of nuclear medicine beds in the German hospital sector].

Nuklearmedizin 2021; 60(3): 216-223; Impact Factor=2.221; Impact Factor 2024=1.2; Typ=English Abstract;Journal Article;

Zippel C, Giesel FL, Kratochwil C, Eiber M, Rahbar K, **Albers P**, Maurer T, Krause BJ, Bohnet-Joschko S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 468990

Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.

Oncologist 2021; 26(12): 1026-1034; Impact Factor=5.837; Impact Factor 2024=4.2; Typ=Journal Article;Research Support, Non-U.S. Gov't;

Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, **Niegisch G**, Dorff TB, Galsky MD, Yu EY

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 383596

Cisplatin-refractory germ cell tumours-molecular background and clinical concepts

Onkologe 2021; 27(1): 46-53; Impact Factor=0.17; Impact Factor 2024=n.a.; Typ=Article;

Bokemeyer C, **Skowron MA**, Peters MC, **Nettersheim D**, Oing C

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 382595

Current developments and treatment options in the management of growing teratoma syndrome

Onkologe 2021; 27(1): 21-28; Impact Factor=0.17; Impact Factor 2024=n.a.; Typ=Article;

Skowron MA, **Hiester A**, Paffenholz P, Nestler T, Heidenreich A, **Albers P**, **Nettersheim D**

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 348860

Importance of residual tumor resection and desperation surgery in advanced germ cell tumors

Onkologe 2021; 27(1): 29-35; Impact Factor=0.17; Impact Factor 2024=n.a.; Typ=Article;

Hiester A, Paffenholz P, **Albers P**, Heidenreich A, Pfister D

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 348935

Therapy options in seminoma stage I and II taking into account long-term toxicities

Onkologe 2021; 27(1): 5-12; Impact Factor=0.17; Impact Factor 2024=n.a.; Typ=Article;

Papachristofilou A, **Hiester A**, Zschaebitz S, Mueller AC
Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 464777

Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.

PLoS ONE 2021; 16(4): ; Impact Factor=3.752; Impact Factor 2024=2.6; Typ=Journal Article;
Ziayee F, Ullrich T, Blondin D, Irmer H, **Arsov C**, Antoch G, Quentin M, Schimmöller L
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 420006

Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragenital and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy.

Urol Int 2021; 105(3-4): 181-191; Impact Factor=1.934; Impact Factor 2024=1.3; Typ=Journal Article;Review;

Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzlbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, **Lorch A**, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 416115

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages.

Urol Int 2021; 105(3-4): 169-180; Impact Factor=1.934; Impact Factor 2024=1.3; Typ=Journal Article;Review;

Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzlbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, **Lorch A**, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 427901

[Avelumab after platinum-based chemotherapy].

Urologe A 2021; 60(5): 640-641; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Journal Article;
Niegisch G, Worst TS

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 470640

[Circulating tumor DNA (ctDNA) in urothelial carcinoma-the long-desired biomarker?].

Urologe A 2021; 60(11): 1466-1467; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Journal Article;

Grunewald CM, Niegisch G

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 473961

[Imaging of oligometastatic disease in selected urologic cancers].

Urologe A 2021; 60(12): 1561-1569; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Journal Article;Review;

Koerber SA, Fink CA, Dendl K, Schmitt D, **Niegisch G**, Mamlins E, Giesel FL

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 465353

[Prostate cancer screening 2021 : Individualization, informed decision-making and additional diagnostic options are good for the disease and those affected].

Urologe A 2021; 60(5): 565-566; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Editorial;

Michel MS, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 464500

[Risk-adapted prostate cancer screening-update 2021].

Urologe A 2021; 60(5): 592-601; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Journal

Article;Review;

Al-Monajjed R, Arsov C, Albers P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 467304

[The PRECISE study: change or standstill in PCa diagnostics?].

Urologe A 2021; 60(10): 1336-1338; Impact Factor=0.803; Impact Factor 2024=n.a.; Typ=Journal Article;

Al-Monajjed R, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 348913

Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome.

World J Urol 2021; 39(7): 2579-2585; Impact Factor=3.661; Impact Factor 2024=2.9; Typ=Journal Article;

Sponholz S, Chalepaki Ntelli K, Karaindros G, Schirren M, Lorch A, **Hiester A, Albers P**, Schirren J

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 279944

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.

World J Urol 2021; 39(1): 65-72; Impact Factor=3.661; Impact Factor 2024=2.9; Typ=Journal Article;

Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 429397

The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).

World J Urol 2021; 39(9): 3407-3414; Impact Factor=3.661; Impact Factor 2024=2.9; Typ=Journal Article;

Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J,

Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, **Lorch A**, **Fingerhut A**, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

